Plain-English translation of NCT05867602 on ClinicalTrials.gov ↗ ·
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing whether giving higher doses of human —a natural protein from blood—on a regular basis can help patients with advanced liver disease manage dangerous fluid buildup in their belly and around their lungs. Right now, doctors treat this fluid buildup by draining it out, but patients often need repeated drains. The study wants to see if regular infusions can prevent the fluid from building up in the first place, so patients need fewer drains and feel better overall.
Patients with severe liver disease often have low levels of natural in their blood, which leads to fluid collecting in their abdomen and around their lungs. While doctors can drain this fluid, it often comes back quickly. This trial is testing whether giving the medication regularly might prevent the fluid from building up so much, reducing how often patients need draining procedures and helping them avoid serious complications.
You likely qualify if…
You likely don't qualify if…
If you join this trial, you will be randomly assigned to either receive weekly infusions along with standard care, or to receive standard care alone (salt restriction and water pills). Both groups will get when large fluid drains are needed. The study will track how often you need drainage procedures, how much fluid is removed, your hospital visits, and your health over 12 months. You will have regular check-ups to monitor your liver function, kidney function, blood sodium levels, and overall quality of life.
AI-generated summary from trial data · Jul 9, 2026 · Not medical advice
United States